Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 1/2008

01-01-2008 | Original Paper

Cognitive Executive Functioning in Relation to HIV Medication Adherence Among Gay, Bisexual, and other Men who have Sex with Men

Authors: Todd M. Solomon, Perry N. Halkitis

Published in: AIDS and Behavior | Issue 1/2008

Login to get access

Abstract

A longitudinal study of 300 HIV-positive gay, bisexual or non-gay-identified men-who-have-sex-with-men was undertaken to consider patterns relating to HIV medication adherence. The purpose of our analyses was to consider the rate of adherence in relation to both age and executive functioning as assessed by the Trail Making Test A and B. Executive functioning was assessed at baseline and month 10. Our analytic sample consisted of 213 men who remained on the same protease inhibitor throughout the assessment timeframe. Adherence rates were relatively high with more than 50% of the sample maintaining a 95%+ adherence rate at both baseline and month 10. Analyses at baseline indicated executive functioning and age were related to rate of adherence. Analyses at month 10 indicated no significant relations. Findings support previous research and suggest that the status of executive functioning as well as age be given consideration when working with HIV-positive individuals.
Literature
Albert, S. M., Todak, G., Elkin, E., Marder, K., Dooneief, G., & Stern Y. (1994). Time allocation and disability in HIV infection: A correlational study. Journal of Occupational Science, 1, 21–30.
Albert, S. M., Marder, K., Dooneief, G., Bell, K., Sano, M., & Todak, G. et al. (1995). Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Archives of Neurology, 52(5), 525–530.
Ammassari, A., Antinori, A., Aloisi, M. S., Trotta, M. P., Murri, R., & Bartoli, L. et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45(5), 394–402.CrossRefPubMed
Ammassari, A. A., Starace, F., Aloisi, M. S., Trotta, M. P., Murri, R., & D’Arminio Monforte, A. et al. (2003). Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity. Neurology, 61(5), 723–4; author reply 724.
Arbuthnott, K., & Frank, J. (2000). Trail making test, part B as a measure of executive control: Validation using a set-switching paradigm. Journal of Clinical and Experimental Neuropsychology: Official Journal of the International Neuropsychological Society, 22(4), 518–528.
Army Individual Test Battery (1944). Manuel of directions and scoring. Washington, DC: War Department, Adjutant General’s Office.
Avants, S. K., Margolin, A., Warburton, L. A., Hawkins, K. A., & Shi, J. (2001). Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions, 10(1), 69–78.PubMed
Baldewicz, T. T., Leserman, J., Silva, S. G., Petitto, J. M., Golden, R. N., & Perkins, D. O. et al. (2004). Changes in neuropsychological functioning with progression of HIV-1 infection: Results of an 8-year longitudinal investigation. AIDS and Behavior, 8(3), 345–355.CrossRefPubMed
Bondi, M. W., Drake, A. I., & Grant, I. (1998). Verbal learning and memory in alcohol abusers and polysubstance abusers with concurrent alcohol abuse. Journal of the International Neuropsychological Society: JINS, 4(4), 319–328.PubMed
Bornstein, R. A., Nasrallah, H. A., Para, M. F., Whitacre, C. C., Rosenberger, P., & Fass, R. J. et al. (1992). Neuropsychological performance in asymptomatic HIV infection. The Journal of Neuropsychiatry and Clinical Neurosciences, 4(4), 386–394.PubMed
Bybee, J. A., & Zigler, E. (1991). Self-image and guilt: A further test of the cognitive-developmental formulation. Journal of Personality, 59(4), 733–745.CrossRefPubMed
Carrieri, P., Cailleton, V., Le Moing, V., Spire, B., Dellamonica, P., & Bouvet, E. et al. (2001). The dynamic of adherence to highly active antiretroviral therapy: Results from the french national APROCO cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 28(3), 232–239.
Cohen, R. A., Boland, R., Paul, R., Tashima, K. T., Schoenbaum, E. E., & Celentano, D. D. et al. (2001). Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS (London, England), 15(3), 341–345.
d’Arminio Monforte, A., Lepri, A. C., Rezza, G., Pezzotti, P., Antinori, A., & Phillips, A. N. et al. (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. study group. Italian cohort of antiretroviral-naive patients. AIDS (London, England), 14(5), 499–507.
Di Stefano, M., Monno, L., Fiore, J. R., Buccoliero, G., Appice, A., & Perulli, L. M. et al. (1998). Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. AIDS (London, England), 12(7), 737–743.
Ellis, R. J., Hsia, K., Spector, S. A., Nelson, J. A., Heaton, R. K., & Wallace, M. R. et al. (1997). Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV neurobehavioral research center group. Annals of Neurology, 42(5), 679–688.CrossRefPubMed
Ferrando, S., van Gorp, W., McElhiney, M., Goggin, K., Sewell, M., & Rabkin, J. (1998). Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function. AIDS (London, England), 12(8), F65–F70.
Ferrando, S. J., Rabkin, J. G., van Gorp, W., Lin, S. H., & McElhiney, M. (2003). Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. The Journal of Neuropsychiatry and Clinical Neurosciences, 15(2), 208–214.PubMed
Gass, C. S., & Daniel, S. K. (1990). Emotional impact on trail making test performance. Psychological Reports, 67(2), 435–438.CrossRefPubMed
Gaudino, E. A., Geisler, M. W., & Squires, N. K. (1995). Construct validity in the trail making test: What makes part B harder? Journal of Clinical and Experimental Neuropsychology: Official Journal of the International Neuropsychological Society, 17(4), 529–535.
Goodkin, K., Wilkie, F. L., Concha, M., Hinkin, C. H., Symes, S., & Baldewicz, T. T. et al. (2001). Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. Journal of Clinical Epidemiology, 54(Suppl. 1), S35–S43.CrossRefPubMed
Gross, R., Bilker, W. B., Friedman, H. M., & Strom, B. L. (2001). Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS (London, England), 15(16), 2109–2117.
Halkitis, P. N., Kutnick, A. H., & Slater, S. (2005). The social realities of adherence to protease inhibitor regimens: Substance use, health care and psychological states. Journal of Health Psychology, 10(4), 545–558.CrossRefPubMed
Heaton, R. K., Grant, I., Butters, N., White, D. A., Kirson, D., & Atkinson, J. H. et al. (1995). The HNRC 500–Neuropsychology of HIV infection at different disease stages. HIV neurobehavioral research center. Journal of the International Neuropsychological Society: JINS, 1(3), 231–251.PubMedCrossRef
Heaton, R. K., Marcotte, T. D., Mindt, M. R., Sadek, J., Moore, D. J., & Bentley, H. et al. (2004). The impact of HIV-associated neuropsychological impairment on everyday functioning. Journal of the International Neuropsychological Society: JINS, 10(3), 317–331.CrossRefPubMed
Hill, Z., Kendall, C., & Fernandez, M. (2003). Patterns of adherence to antiretrovirals: Why adherence has no simple measure. AIDS Patient Care and STDs, 17(10), 519–525.CrossRefPubMed
Hinkin, C. H., Castellon, S. A., Durvasula, R. S., Hardy, D. J., Lam, M. N., & Mason, K. I. et al. (2002). Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity. Neurology, 59(12), 1944–1950.PubMed
Hinkin, C. H., Hardy, D. J., Mason, K. I., Castellon, S. A., Durvasula, R. S., & Lam, M. N. et al. (2004). Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS (London, England), 18(Suppl. 1), S19–S25.
Hugen, P. W., Langebeek, N., Burger, D. M., Zomer, B., van Leusen, R., & Schuurman, R. et al. (2002). Assessment of adherence to HIV protease inhibitors: Comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Journal of Acquired Immune Deficiency Syndromes (1999), 30(3), 324–334.
Kalichman, S. C., Difonzo, K., Austin, J., Luke, W., & Rompa, D. (2002). Prospective study of emotional reactions to changes in HIV viral load. AIDS Patient Care and STDs, 16(3), 113–120.CrossRefPubMed
Kimmerling, M., Wagner, G., & Ghosh-Dastidar, B. (2003). Factors associated with accurate self-reported adherence to HIV antiretrovirals. International Journal of STD and AIDS, 14(4), 281–284.CrossRefPubMed
Kortte, K. B., Horner, M. D., & Windham, W. K. (2002). The trail making test, part B: Cognitive flexibility or ability to maintain set? Applied Neuropsychology, 9(2), 106–109.CrossRefPubMed
Kruse, W., Rampmaier, J., Ullrich, G., & Weber, E. (1994). Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care. International Journal of Clinical Pharmacology Therapy, 32, 453–457.
Lezak, M. D. (1995). Neuropsychological assessment (3rd ed.). New York: Oxford University Press.
Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., & Sanandaji, S. et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134(10), 968–977.PubMed
Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 34(8), 1115–1121.
Matsuyama, J. R., Mason, B. J., & Jue, S. G. (1993). Pharmacists’ interventions using an electronic medication-event monitoring device’s adherence data versus pill counts. The Annals of Pharmacotherapy, 27(7–8), 851–855.PubMed
McArthur, J. C., McClernon, D. R., Cronin, M. F., Nance-Sproson, T. E., Saah, A. J., & St Clair, M. et al. (1997). Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Annals of Neurology, 42(5), 689–698.CrossRefPubMed
Miller, E. N., Selnes, O. A., McArthur, J. C., Satz, P., Becker, J. T., & Cohen, B. A. et al. (1990). Neuropsychological performance in HIV-1-infected homosexual men: The multicenter AIDS cohort study (MACS). Neurology, 40(2), 197–203.PubMed
Palella, F. J. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., & Satten, G. A. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. The New England Journal of Medicine, 338(13), 853–860.CrossRefPubMed
Parsons, T. D., Braaten, A. J., Hall, C. D., & Robertson, K. R. (2006). Better quality of life with neuropsychological improvement on HAART. Health and Quality of Life Outcomes [Electronic Resource], 4, 11.CrossRef
Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., & Squier, C. et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21–30.PubMed
Power, R., Koopman, C., Volk, J., Israelski, D. M., Stone, L., & Chesney, M. A. et al. (2003). Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected persons. AIDS Patient Care and STDs, 17(5), 245–252.CrossRefPubMed
Rabkin, J. G., & Chesney, M. (1999). Treatment adherence to HIV medications: The Achilles heel of new therapeutics. In D. Ostrow, S. Kalichman (Eds.), New HIV therapies: Psychology and public health implications. New York: Plenum Press.
Reger, M., Welsh, R., Razani, J., Martin, D. J., & Boone, K. B. (2002). A meta-analysis of the neuropsychological sequelae of HIV infection. Journal of the International Neuropsychological Society: JINS, 8(3), 410–424.CrossRefPubMed
Reitan, R., & Wolfson, D. (1993). The helstead-reitan neuropsychological test battery: Theory and clinical interpretation. Tucson, AZ: Neuropsychological Press.
Rosselli, M., & Ardila, A. (1996). Cognitive effects of cocaine and polydrug abuse. Journal of Clinical and Experimental Neuropsychology: Official Journal of the International Neuropsychological Society, 18(1), 122–135.
Sankar, A., Golin, C., Simoni, J. M., Luborsky, M., & Pearson, C. (2006). How qualitative methods contribute to understanding combination antiretroviral therapy adherence. Journal of Acquired Immune Deficiency Syndromes (1999), 43(Suppl. 1), S54–S68.CrossRef
Shannon, K., Kerr, T., Lai, C., Ishida, T., Wood, E., & Montaner, J. S. et al. (2005). Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. Journal of the International Association of Physicians in AIDS Care (Chicago, IL: 2002), 4(3), 66–72.CrossRef
Starace, F., Bartoli, L., Aloisi, M. S., Antinori, A., Narciso, P., & Ippolito, G. et al. (2002). Cognitive and affective disorders associated to HIV infection in the HAART era: Findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. the NeuroICONA study. Acta Psychiatrica Scandinavica, 106(1), 20–26.CrossRefPubMed
Tombaugh, T. N. (2004). Trail making test A and B: Normative data stratified by age and education. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists, 19(2), 203–214.
Tozzi, V., Balestra, P., Galgani, S., Narciso, P., Sampaolesi, A., & Antinori, A. et al. (2001). Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. Journal of Acquired Immune Deficiency Syndromes (1999), 28(1), 19–27.
Tozzi, V., Balestra, P., Murri, R., Galgani, S., Bellagamba, R., & Narciso, P. et al. (2004). Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. International Journal of STD and AIDS, 15(4), 254–259.CrossRefPubMed
Treisman, G. J., Angelino, A. F., & Hutton, H. E. (2001). Psychiatric issues in the management of patients with HIV infection. JAMA: The Journal of the American Medical Association, 286(22), 2857–2864.CrossRef
Turner, C. F., Ku, L., Rogers, S. M., Lindberg, L. D., Pleck, J. H., & Sonenstein, F. L. (1998). Adolescent sexual behavior, drug use, and violence: Increased reporting with computer survey technology. Science, 280(5365), 867–873.CrossRefPubMed
Valcour, V., & Paul, R. (2006). HIV infection and dementia in older adults. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 42(10), 1449–1454.
Wagner, G. J. (2002). Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care and STDs, 16(12), 599–608.CrossRefPubMed
Wagner, G. J., & Rabkin, J. G. (2000). Measuring medication adherence: Are missed doses reported more accurately then perfect adherence? AIDS Care, 12(4), 405–408.CrossRefPubMed
Wainberg, M. A., & Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. JAMA: The Journal of the American Medical Association, 279(24), 1977–1983.CrossRef
Waterhouse, D. M., Calzone, K. A., Mele, C., & Brenner, D. E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 11(6), 1189–1197.
Watters, J. K., & Biernacki, P. (1989). Targeted sampling: Options and considerations for the study of hidden populations. Social Problems, 36, 416–430.CrossRef
Metadata
Title
Cognitive Executive Functioning in Relation to HIV Medication Adherence Among Gay, Bisexual, and other Men who have Sex with Men
Authors
Todd M. Solomon
Perry N. Halkitis
Publication date
01-01-2008
Publisher
Springer US
Published in
AIDS and Behavior / Issue 1/2008
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-007-9273-0

Other articles of this Issue 1/2008

AIDS and Behavior 1/2008 Go to the issue

Original Paper

Emotional Support and Affect: Associations with Health Behaviors and Active Coping Efforts in Men Living with HIV

Original Paper

Increased HIV Risk Associated with Criminal Justice Involvement among Men on Methadone

Original Paper

Optimal Recall Period and Response Task for Self-Reported HIV Medication Adherence

Original Paper

Medication Adherence Mediates the Relationship between Adherence Self-efficacy and Biological Assessments of HIV Health among those with Alcohol Use Disorders

Original Paper

Agreement of Daily Diary and Retrospective Measures of Condom Use

Original Paper

Stigmatization of AIDS Patients: Disentangling Thai Nursing Students’ Attitudes Towards HIV/AIDS, Drug Use, and Commercial Sex
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits